Quintiles Library

Featured Podcast

The Friday Podcast: Direct-to-Patient Registries
...
Show Filters
Video
Discover how Quintiles' Site and Patient Network group is fostering relationships, leveraging technology, and engaging patients.    This is the player to use for single videos on Q.com...
Press Release
RESEARCH TRIANGLE PARK, N.C. – May 20, 2015 – Quintiles CEO Tom Pike will present at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015 in New York City at the Grand Hyatt New York. The Quintiles presentation will begin at 11:30 a.m. (EDT). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 33,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2014’s top-75...
Read More
Presentation
During this webinar, Quintiles experts Eric Faulkner, MPH, Practice Leader, Emerging Technology Value Demonstration, Access & Commercialization and Kathryn Starzyk, Senior Director of Epidemiology, discuss new opportunities for rare diseases, how generating the right evidence can help you meet increasing multi-stakeholder demands, incorporating the patient voice into your research and delivering value at every step of the research process. Authors: Eric Faulkner, MPH, Practice Leader, Emerging Technology Value Demonstration, Access & Commercialization and Kathryn Starzyk, Senior Director of...
Explore More
Press Release
RESEARCH TRIANGLE PARK, NC – May 19 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Of the total shares sold in the offering, Quintiles repurchased 3,855,050 shares from the underwriters at a price of $64.85 per share, which is the same as the price per share paid to the Selling Shareholders by the underwriters. Quintiles did...
Read More
Media Coverage
In this article, Stella Blackburn discusses work conducted by the Innovative Medicines Initiative (IMI) and the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium), led by the European Medicines Agency.  The study looked at whether it’s possible to collect data directly from pregnant women without the intervention of healthcare professionals. The article was published in April 2015 by The Pregnancy & Medicine Initiative, which aims to raise awareness and help address the information vacuum concerning the use of medicines and medical treatment in pregnancy. Visit...
Read More
Fact Sheet
This infographic shows how Quintiles can help lower the costs associated with the ongoing maintenance of your established products while generating additional insights into your portfolio by providing a fully integrated regulatory, safety and benefit-risk management...
Read More
Press Release
Research Triangle Park, NC, May 14, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the pricing of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”) at a price to the public of $65.00 per share. Quintiles intends to repurchase from the underwriters a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the...
Read More
Press Release
Research Triangle Park, NC, May 13, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 11,855,050 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation, Temasek Life Sciences Private Limited and Dennis Gillings, CBE, and his affiliates (the “Selling Shareholders”), of which Quintiles intends to repurchase from the underwriters a number of shares having an aggregate value of approximately $250 million. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this...
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – May 12, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) today announced the completion of its previously announced refinancing.  In the refinancing, the Company’s wholly-owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), entered into new senior secured credit facilities totaling $1.95 billion, consisting of a $500 million revolving credit facility and $1.45 billion of term loans. In addition, Quintiles Transnational completed the offering of its $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).  Net proceeds from the...
Read More
Presentation
This 15 minute video is a response from Jeanne Hecht, Senior Vice President, Site and Patient Networks to a conversation with physician investigators at the CNS Summit. In the presentation, Jeanne acknowledges many of the burdens facing investigators participating in clinical trials, including quality issues and business needs. By applying cutting edge technology to streamline documentation, actively involving all interested parties, and cooperating with our partners and regulatory agencies, we can modernize trials and present a better image to patients. Jeanne also discusses ways we are enhancing patient awareness and participation - all to create a better investigator experience. This is the player to use for single videos on Q.com ...
Explore More
Brochure
最新技術とパートナーシップによって患者データへの新たなアクセスが開発されるに伴い、リアルワールド条件下で製品の有効性と安全性を実証できるエビデンスの作成がこれまでになく重要になっています。 このようなエビデンスを提供してステークホルダーのニーズを満たすことができるのが、観察研究と患者レジストリです。 リアルワールドプログラムでは治験とは異なる設計や実施課題がもたらされるため、治験とは異なる専門知識や能力が要求されます。クインタイルズではこのようなユニークな課題を理解するだけでなく、実証済みの解決方法を構築しています。 コンテンツは日本語です。
Read More
Brochure
ステークホルダーが規制や償還、処方に関わる決定を裏付けるエビデンスをさらに求める中、リアルワールドと市販後調査が製品の成功に欠かせないものとなってきています。新規の試験は、デザインをはじめ、運営、分析、品質保証について新しい科学的水準を満たさなければなりません。 経験豊富な戦略的研究とテクノロジーを提供するパートナーとして、クインタイルズは、お客様のニーズを満たす高品質のプログラムをカスタマイズしてデザインし実施するお手伝いをします。 コンテンツは日本語です。
Read More
Press Release
RESEARCH TRIANGLE PARK, NC – May 6, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today that Quintiles Transnational Corp. (“Quintiles Transnational”), its wholly owned subsidiary, has priced $800 million principal amount of 4.875% senior unsecured notes due 2023 (the “Senior Notes”) offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed senior secured credit facility, which is expected to increase to a total of $1.95 billion, including $1.45 billion of term loans, to refinance its existing credit facility, as well as for...
Read More
Presentation
This presentation will describe the use of Advanced Simulation Engineering (ASE) to develop and add enhancements to Quintiles Infosario® Design, a novel approach to design and plan clinical development programs and trials. ASE offers the following advantages: Rapid, iterative, design to build superior solutions Allows business, IT, and end-users to share an understanding of a software solution The ability to determine the feasibility of a function, scenario or solution without the large investment of coding, developers and infrastructure Provides a visual, validated by stakeholders, that communicates to developers what should be produced in terms of UI and functionality. Addresses perceived shortcomings in a traditional UX approach of not delivering actionable...
Explore More
White Paper
China is now the world’s second largest pharmaceutical market, trailing only the United States.  Even with that size, its companies cannot ignore large Western and developing markets.  This paper examines Chinese biopharmaceutical companies with global growth aspirations – their typical strengths and weaknesses; how to leverage their “Asia advantage” in implementing global growth strategies; market access issues for Europe, the United States and Japan; and other success factors for Chinese companies to become global biopharma powerhouses.  Authors:  Geoff Garabedian, Senior Vice President and Managing Director, Quintiles Advisory Service Christoph Schnorr, MD, Vice President, Quintiles Advisory Services Ling Zhen, JD, MBA, General Manager and Head of Greater China,...
Explore More
Fact Sheet
Healthcare systems across the globe are evolving as expenses rise alongside improvements in care, and the need to control costs becomes paramount. Payers are increasingly demanding proof of value from new medicines, raising the bar for compliance policies and requiring more evidence of patient impact. For today’s drug developers, the emphasis has shifted from “time to market” to “time to access.” By clearly communicating a strategic and cohesive value message to key stakeholders, the path to market access can be navigated more effectively and efficiently.  Discover how Medical Science Liaisons (MSLs) can be an integral part of your team and gain a deeper insight into:  The difference between a traditional sales representative and a MSL  How MSLs can help to prepare the market...
Read More
White Paper
Emerging markets offer significant untapped sales potential for biopharma companies, but bringing a new product to these markets can be complicated, costly and time consuming. In this paper Evangelos Tryfonidis, Vice President of Business Development, Emerging Markets outlines the obstacles small and mid-sized biopharma companies face when entering emerging markets, the benefits and risks of different market access strategies, and how to choose an approach that delivers the most long term value to their business. Author: Evangelos Tryfonidis, Vice President of Business Development, Emerging...
Explore More
Video 01:28
With Quintiles Patient-Centric Real-World Retention, you can retain patients throughout your real-world and late phase research while driving better reporting and compliance. Our expertise balances study design rigor with a differentiated and compelling patient experience. This is the player to use for single videos on Q.com...